Modeling the Long-Term Cost-Effectiveness of IDegLira in Patients with Type 2 Diabetes Who are Failing To Meet Glycemic Targets on Basal Insulin Alone in The Netherlands

Table 1 Baseline cohort characteristics

Characteristic	DUAL II^c cohort (patients receiving IDegLira)
Demographics and risk factors, mean (SD)
Start age (years)	56.8 (8.9)
Duration of diabetes (years)	10.3 (6.0)
Percentage male (%)	56.3
HbA_1c (%)	8.7 (0.7)
SBP (mmHg)	132.4 (14.8)
Total cholesterol (mg/dL)	182.0 (45.5)
HDL cholesterol (mg/dL)	43.4 (11.0)
LDL cholesterol (mg/dL)	101.9 (37.1)
Triglycerides (mg/dL)	196.8 (148.0)
BMI (kg/m²)	33.6 (5.7)
Percentage smokers (%)	16.1
Cigarettes per day^a	12.7
Alcohol consumption (fl oz/week)^b	4.66
Ethnic group, %
White	70.9
Black	4.5
Hispanic	8.0
Native American	0
Asian/Pacific Islander	16.6

BMI body mass index, HbA _1c glycated hemoglobin, HDL high-density lipoprotein, LDL low-density lipoprotein, SBP systolic blood pressure
^aFrom [16]
^bFrom [17]
^cDUAL II is a randomized, controlled, double-blind, multinational, treat-to-target trial in which IDegLira was compared with IDeg over 26 weeks of treatment in patients with T2DM uncontrolled on basal insulin [7]